BMS-345541: A Potent IKK-1/IKK-2 Inhibitor for NF-κB Research

Executive Summary: BMS-345541 (free base) is a small molecule inhibitor with high selectivity for IKK-1 and IKK-2, central kinases in the NF-κB pathway. It achieves allosteric inhibition with IC₅₀ values of 4 μM (IKK-1) and 0.3 μM (IKK-2) (source: product_spec). In cell-based assays, it potently suppresses cytokine-induced phosphorylation of IKK and downstream inflammatory cytokine production (source: DOI). BMS-345541 is effective in both in vitro and in vivo models, including suppression of LPS-induced TNF in mice (source: product_spec). Its solubility profile and storage guidelines enable reliable integration into diverse research workflows. APExBIO supplies BMS-345541 (SKU B4655) validated for experimental reproducibility in inflammation, apoptosis, and angiogenesis studies.

Biological Rationale

Aberrant activation of the NF-κB pathway is implicated in inflammatory diseases, cancer, and angiogenesis (source: DOI). IκB kinases (IKK-1/IKK-2) phosphorylate IκB proteins, triggering NF-κB nuclear translocation and transcription of pro-inflammatory cytokines. Selectively inhibiting these kinases enables researchers to dissect the contribution of NF-κB signaling to disease phenotypes and therapeutic responses. BMS-345541 is a widely adopted tool for such studies due to its specificity and reversible action (source: internal_article).

Mechanism of Action of BMS-345541 (free base)

BMS-345541 binds to an allosteric site on IKK-1 and IKK-2, rather than the ATP-binding pocket (source: product_spec). This binding mode confers selectivity, reducing off-target kinase inhibition. By blocking IKK activation, BMS-345541 prevents phosphorylation and degradation of IκBα, thereby retaining NF-κB in the cytoplasm and suppressing its transcriptional activity. In cellular models such as THP-1 monocytes, pre-treatment with BMS-345541 reduces phosphorylation of IKK and subsequent expression of TNF-α, IL-1β, IL-6, and IL-8 (source: DOI).

Evidence & Benchmarks

• BMS-345541 exhibits an IC₅₀ of 0.3 μM for IKK-2 and 4 μM for IKK-1, reflecting high selectivity for canonical NF-κB pathway inhibition (source: product_spec).
• In THP-1 monocytes, BMS-345541 suppresses cytokine-induced phosphorylation of IKK and downstream production of TNF-α, IL-1β, IL-6, and IL-8 (source: DOI).
• In murine models, intravenous or oral dosing at 3–100 mg/kg significantly reduces LPS-induced serum TNF levels (source: product_spec).
• BMS-345541 has demonstrated capacity to reduce proliferation and induce apoptosis in glioma and melanoma cell lines (source: internal_article).
• In critical limb ischemia models, BMS-345541 counteracts pro-angiogenic effects induced by thymosin-β 4, via suppression of the Notch/NF-κB axis (source: DOI).

For a detailed scenario-driven guide to cell viability and cytokine modulation assays using BMS-345541, see the Optimizing NF-κB Pathway Studies article, which this dossier extends by adding quantitative in vivo benchmarks and updated storage recommendations.

Applications, Limits & Misconceptions

BMS-345541 is used to dissect NF-κB-dependent transcription in inflammation research, apoptosis induction in cancer cells, and angiogenesis studies. It is particularly valuable in workflows requiring selective IκB kinase inhibition without broad off-target effects. However, its use is limited in contexts where non-canonical NF-κB signaling predominates or where ATP-competitive inhibition is required. BMS-345541's insolubility in water necessitates careful solvent choice and handling (source: product_spec).

Common Pitfalls or Misconceptions

• BMS-345541 is not effective in models where NF-κB activation is independent of IKK-1/IKK-2.
• ATP-competitive kinase assays may underestimate its efficacy due to its allosteric mode of action.
• Failure to use DMSO or ethanol as recommended solvents can lead to precipitation and assay variability.
• Long-term storage of BMS-345541 solutions is not recommended; fresh preparation is necessary for reproducibility.
• BMS-345541 does not inhibit upstream signaling pathways unrelated to IKK activation.

For additional troubleshooting and advanced use-cases, the article IKK-1/IKK-2 Inhibitor for Inflammation & Cancer Research provides workflow strategies. This present dossier clarifies the mechanistic selectivity and expands evidence for in vivo efficacy over previous reviews.

Workflow Integration & Parameters

Integration of BMS-345541 into experimental workflows requires attention to solvent compatibility, dosing, and incubation times. Below are practical parameters and rationale for common assays:

Protocol Parameters

• in vitro kinase inhibition | 0.3–4 μM | IKK-1/IKK-2 activity assays | Matches reported IC₅₀ range for specific inhibition | product_spec
• cell-based cytokine suppression | 1–10 μM | THP-1 or similar monocytes | Yields robust reduction in TNF-α, IL-1β, IL-6, IL-8 | DOI
• proliferation/apoptosis in cancer cells | 5–20 μM | glioma, melanoma cell lines | Induces apoptosis, suppresses proliferation | internal_article
• angiogenesis modulation | 10 μM | HUVEC, CLI mouse models | Used to counteract Tβ4-induced angiogenesis via NF-κB inhibition | DOI
• in vivo LPS challenge | 3–100 mg/kg, IV/PO | BALB/c mice | Dose-dependent TNF suppression | product_spec
• solubility | ≥70 mg/mL in DMSO; ≥2.49 mg/mL in EtOH | solution prep | For optimal dissolution and reproducibility | product_spec
• storage | -20°C (solid); fresh solution | all assays | Ensures compound integrity and potency | product_spec

For advanced experimental guidance and troubleshooting, refer to Precision IKK-1/IKK-2 Inhibition in Angiogenesis Research. This document updates best practices for solvent handling and storage, building on prior workflow recommendations.

Conclusion & Outlook

BMS-345541 (free base) offers precise, allosteric inhibition of IKK-1/IKK-2, enabling robust dissection of NF-κB-mediated events in inflammation research, cancer cell apoptosis, and angiogenesis modulation. Its reproducible suppression of cytokine production and validated in vivo efficacy make it a reference tool for both basic and translational studies (source: DOI). As highlighted by APExBIO, careful adherence to solvent and storage parameters ensures optimal performance. Future research will continue to refine its applications in disease models where canonical NF-κB signaling is central, but limitations remain in non-canonical contexts and with long-term solution storage.